Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Reference Study ID Number: BX44273 https://forpatients.roche.com/ 888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Back

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Recruiting

Open to: ALL

Age: 18.0 - N/A

Leicester Surrey

Medical Conditions

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2023 Mar 2033

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche IMP(s) Monotherapy;

Intervention Type : DRUG
Intervention Description : Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche Combined Agents;

Intervention Type : DRUG
Intervention Description : Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.

Intervention Arm Group : Roche Combined Agents;Roche IMP(s) Monotherapy;

Intervention Type : DRUG
Intervention Description : Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche Combined Agents;

Intervention Type : DRUG
Intervention Description : Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche Combined Agents;Roche IMP(s) Monotherapy;

Intervention Type : DRUG
Intervention Description : Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche IMP(s) Monotherapy;

Intervention Type : DRUG
Intervention Description : Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Intervention Arm Group : Roche Combined Agents;Roche IMP(s) Monotherapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Leicester Royal Infirmary
    Leicester
    LE1 5WW
  • Royal Marsden Hospital - Surrey
    Surrey
    SM2 5PT

Reference Study ID Number: BX44273 https://forpatients.roche.com/ 888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com



The study is sponsored by Hoffmann-La Roche



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05862285
Last updated 12 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top